Afatinib Plus Nimotuzumb for NSCLC
To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to gefitinib or erlotinib.
NSCLC
DRUG: afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)
Maximal tolerated dose, To establish maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for BIBW 2992 and nimotuzumab in patients with acquired resistance to erlotinib or gefitinib, 4 weeks
To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to gefitinib or erlotinib.